Industry
Biotechnology
BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing immunotherapies for the treatment of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, a personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test. BriaCell Therapeutics Corp. is headquartered in West Vancouver, Canada.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Benzinga Newsdesk
July 18, 2024 | 11:58 am
Portfolio Pulse from Benzinga Newsdesk
June 04, 2024 | 10:54 am
Portfolio Pulse from Benzinga Newsdesk
June 03, 2024 | 12:29 pm
Portfolio Pulse from Benzinga Newsdesk
May 30, 2024 | 12:09 pm
Portfolio Pulse from Benzinga Newsdesk
May 28, 2024 | 12:28 pm
Portfolio Pulse from Benzinga Newsdesk
May 24, 2024 | 12:05 pm
Portfolio Pulse from Benzinga Newsdesk
May 24, 2024 | 11:24 am
Portfolio Pulse from Benzinga Newsdesk
May 15, 2024 | 4:36 pm
Portfolio Pulse from Benzinga Newsdesk
April 09, 2024 | 12:49 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.